- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC | Clinical
Goals for TACE and Immunotherapy Trial in Intermediate-Stage HCC
November 08, 2021
Arndt Vogel, MD, discusses the goals of the IMMUTACE study investigating the efficacy of transarterial chemoembolization with nivolumab in patients with intermediate-stage hepatocellular carcinoma.
Early-Stage Immunotherapy Use in HCC Produces High Response Rate
October 28, 2021
Lead investigator Arndt Vogel, MD, discussed the use of immunotherapy in earlier-stage HCC and findings from the IMMUTACE in an interview with Targeted Oncology.
Abou-Alfa Gives Expert Insights for Liver Cancer Awareness Month
October 20, 2021
Ghassan K. Abou-Alfa, MD, reviews the liver cancer landscape and the collaboration of Memorial Sloan Kettering Cancer Center with other institutions to further treatments in this setting.
Roundtable Discussion: Singal Explains Options for Frontline Treatment in Unresectable Hepatocellular Carcinoma Care
October 17, 2021
A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.
Tremelimumab and Durvalumab Improves OS in Advanced Hepatocellular Carcinoma
October 15, 2021
The HIMALAYA study has met its primary end point of overall survival improvement in patients with unresectable hepatocellular carcinoma with tremelimumab plus durvalumab.
Investigating TACE With Nivolumab in Hepatocellular Carcinoma
October 12, 2021
Arndt Vogel, MD, discusses the trial design of IMMUTACE, which is evaluating the efficacy of transarterial chemoembolization in combination with nivolumab for the treatment of intermediate-stage hepatocellular carcinoma.
Vogel Discusses Real-World Survival Data of Immunotherapy in HCC
October 10, 2021
Arndt Vogel, MD, the managing senior consultant and professor in the department of Gastroenterology, Hepatology, and Endocrinology, at the Hannover Medical School, discusses the real-world data of immunotherapy combinations in hepatocellular carcinoma.
Roundtable Discussion: Abou-Alfa and Participants Cover Biopsies and Treatment in HCC
October 08, 2021
A 77-year-old woman presented to her primary care physician complaining of abdominal pain and fatigue. Ghassan K. Abou-Alfa, MD, discussed the case with a group of physicians.
Presence of High Interferon Signaling, MHC Class II–Related Genes Suggest Biomarkers of Response in HCC
October 06, 2021
Most patients with advanced HCC have resistance to PD-1 monotherapy. In other cancers, response to PD-1 inhibitors has been associated with an inflamed microenvironment with effector T cells and active IFN-α signaling.
Understanding irAEs Is Vital for IO Combo Use in HCC
October 05, 2021
In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.